NLK is a member of the mitogen-activated protein kinase family that regulates a wide range of transcription factors [40], and it is considered a tumor suppressor targeting Wnt/β-catenin signaling pathway in diverse cancers, such as ovarian cancer [41], glioma [42], and hepatocellular cancer [43]. The gene discussed is NLK; the disease is central nervous system cancer.